Regenxbio Shares Rise After Positive Duchenne Trial Results

Regenxbio (NASDAQ:RGNX) shares gained much than 4% successful premarket trading Thursday aft investors focused connected encouraging objective proceedings results for the company’s Duchenne muscular dystrophy therapy, contempt weaker-than-expected quarterly fiscal results.

Earnings and Revenue Miss Expectations

Regenxbio reported a first-quarter nonaccomplishment of $1.72 per share, wider than expert expectations of a $1.34 nonaccomplishment per share.

Revenue totaled $6.39 million, good beneath the statement estimation of $25.8 million.

The company’s gross declined 93% year-on-year from $89.0 cardinal successful the archetypal 4th of 2025.

Regenxbio said the driblet was mostly owed to a $70 cardinal upfront licence outgo from Nippon Shinyaku recognized successful the prior-year period, arsenic good arsenic a $12.2 cardinal simplification successful ZOLGENSMA royalty gross aft definite licensed U.S. patents expired successful January 2026.

Duchenne Trial Meets Primary Endpoint

Investor sentiment improved aft the institution announced affirmative topline results from the pivotal Phase III AFFINITY DUCHENNE proceedings evaluating RGX-202.

According to Regenxbio, the survey achieved its superior endpoint with precocious statistical significance.

The institution said 93% of patients reached RGX-202 microdystrophin look levels supra 10%, with a reported p-value of little than 0.0001.

The attraction besides demonstrated a statistically important narration betwixt microdystrophin look and functional improvement.

CEO Highlights Transformational Year

President and main enforcement Curran Simpson said the institution continues to marque advancement crossed its late-stage pipeline.

“REGENXBIO enters a transformative twelvemonth with affirmative momentum, reaching important late-stage milestones to enactment our imaginable first- and best-in-class cistron therapies,” Simpson said.

Research Spending Continues to Increase

Research and improvement expenses roseate to $57.3 cardinal from $53.1 cardinal successful the prior-year quarter.

The summation was chiefly linked to objective proceedings costs associated with RGX-202, on with higher unit expenses.

General and administrative expenses besides accrued modestly to $21.3 cardinal from $20.3 cardinal a twelvemonth earlier.

Cash Position Expected to Support Operations Into 2027

As of March 31, 2026, Regenxbio held $150.5 cardinal successful cash, currency equivalents and marketable securities.

The institution said its existent liquidity is expected to money operations into aboriginal 2027.

This outlook excludes immoderate imaginable aboriginal milestone payments from partners.

Regenxbio besides said it expects to person a $100 cardinal milestone outgo from AbbVie erstwhile the archetypal diligent is dosed successful the Phase IIb information of the NAAVIGATE study, which is expected during the 2nd 4th of 2026.

Regenxbio banal price